Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q2 Losses Up on Spinout-Related Expenses

Premium

RXi Pharmaceuticals this week released its second-quarter financial results, posting a surge in losses tied to its spinout from former parent firm Galena Biopharma (GSN 5/10/2012).

For the three-month period ended June 30, RXi's net loss jumped to $17.2 million, or $0.13 a share, from a year-ago loss of $1.9 million, or $0.05 a share. According to the company, the increase was largely the result of a $9.6 million non-cash dividend “relating to the beneficial conversion feature as a result of the issuance of convertible preferred stock” in late April when Galena sold 83 percent of RXi to institutional shareholders.

RXi's research and development spending soared to $6.9 million from $1.8 million during the same period last year, a rise in part related to costs associated with the acquisition of patent and technology rights during the spin-off process.

General and administrative costs, meantime, fell to $700,000 from $1 million.

At the end of the second quarter, RXi had cash and cash equivalents totaling $7.6 million, which it said should be sufficient to fund operations into the second quarter of next year.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.